Axcella Kickstarts Long COVID Phase 2 Clinical Trial

Axcella Therapeutics Inc AXLA has started patient screening in a Phase 2a trial of AXA1125, an oral product candidate, as a potential treatment for Long COVID.

  • Phase 2a evaluates the efficacy and safety of AXA1125 in patients with exertional fatigue related to Long COVID. 
  • Approximately 40 patients in the U.K. will be enrolled and randomized evenly to receive either 67.8 grams per day of AXA1125 or a matched placebo in two divided doses for 28 days, with a one-week safety follow-up period.
  • Related Link: Axcella To Test NASH Candidate In Long COVID Patients.
  • The primary endpoint in this Phase 2a trial is the change from baseline to Day 28 in phosphocreatine (PCr) recovery time. 
  • In past clinical trials, the highly sensitive and well-established measure of mitochondrial function has been correlated with the six-minute walk test, a registrational endpoint in other conditions involving fatigue. 
  • Key secondary endpoints in the Phase 2a trial include lactate levels (a serum marker of mitochondrial dysfunction), six-minute walk test, fatigue scores, and safety and tolerability.
  • Top-line data are expected to be reported from the Phase 2a trial in mid-2022.
  • Price Action: AXLA shares are up 4.24% at $2.46 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!